Ionis

The U.S. Food and Drug Administration approved in late December Ionis Pharmaceuticals Inc's (NASDAQ: IONS) therapy for the treatment of spinal muscular atrophy called Spinraza. In a research report on Friday, Jefferies' Eun Yang suggested that Spinraza is Ionis' only exciting...

Citron Research's latest target is AveXis Inc (NASDAQ: AVXS), a clinical-stage gene therapy company that focuses on creating gene therapy treatments for patients suffering from neurological genetic diseases. Citron Research, the notable short-selling research firm, blasted AveXis in a report dated...